stocktitan.net

Bristol Myers Squibb Presents 5-Year Camzyos Efficacy and Safety Data

Bristol-Myers Squibb logoBristol-Myers Squibb
Sig2.20Sen+3.48Env0.00Soc+0.93Gov+0.28

Bristol Myers Squibb presented up to five years of data at the ESC Congress 2026 supporting Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy. Results from EXPLORER-LTE showed sustained effects with 69.6% improving by at least one NYHA class and 59.2% becoming asymptomatic, while safety matched prior findings; real-world studies reinforced effectiveness and safety for treatment decisions.

Coverage (2)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro